Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026

Core Insights - Edgewise Therapeutics, Inc. (NASDAQ:EWTX) is recognized as one of the top 14 booming stocks to buy, with a stock price increase of over 57% in the last three months as of January 12 [1] Company Updates - On January 13, Edgewise Therapeutics closed 3% higher after providing a corporate update and outlining its priorities for 2026 [2] - Major milestones for 2026 include expected top-line findings for Sevasemten by Q4, which would be the first approved therapy for Becker disease [2] - The company anticipates Phase 2 results for its selective cardiac sarcomere modulator, EDG-7500, in the first half of the year, aimed at treating hypertrophic cardiomyopathy (HCM) [2] Analyst Ratings - The stock has a one-year average share price target of $38.14, indicating an upside potential of 58.06% as of January 12 [2] - Wall Street analysts maintain a consensus Strong Buy rating for Edgewise Therapeutics [2] - Stifel Nicolaus has a Hold rating with a $16 price target, while JPMorgan has reiterated an Overweight rating on the stock [2] Company Profile - Edgewise Therapeutics is a biopharmaceutical company focused on developing therapeutics for muscular dystrophies and cardiac diseases [2]